V. S. Zimmermann
Tumors hamper the immunogenic competence of CD4+T cell-directed dendritic cell vaccination
Zimmermann, V. S.; Casati, A.; Schiering, C.; Caserta, S.; Hess Michelini, R.; Basso, V.; Mondino, A.
Dr Stefano Caserta S.Caserta@hull.ac.uk
Lecturer in Immunology
R. Hess Michelini
Dendritic cells loaded with tumor-derived peptides induce protective CTL responses and are under evaluation in clinical trails. We report in this study that prophylactic administration of dendritic cells loaded with a MHC class II-restricted peptide derived from a model tumor Ag (Leishmania receptor for activated C kinase (LACK)) confers protection against LACK-expressing TS/A tumors, whereas therapeutic vaccination fails to cure tumor-bearing mice. Although CD4 + T cell-directed dendritic cell vaccination primed effector-like (CD44 high CD62L low , IL-2 + , IFN-γ + ) and central memory-like lymphocytes (CD44 high CD62L high , only IL-2 + ) in tumor-free mice, this was not the case in tumor-bearing animals in which both priming and persistence of CD4 + T cell memory were suppressed. Suppression was specific for the tumor-associated Ag LACK, and did not depend on CD25 + T cells. Because T cell help is needed for protective immunity, we speculate that the ability of tumors to limit vaccine-induced CD4 + T cell memory could provide a partial explanation for the limited efficacy of current strategies.
|Journal Article Type||Article|
|Publication Date||Sep 1, 2007|
|Journal||Journal of Immunology|
|Publisher||American Association of Immunologists|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Zimmermann, V. S., Casati, A., Schiering, C., Caserta, S., Hess Michelini, R., Basso, V., & Mondino, A. (2007). Tumors hamper the immunogenic competence of CD4+T cell-directed dendritic cell vaccination. Journal of Immunology, 179(5), 2899-2909. https://doi.org/10.4049/jimmunol.179.5.2899|
You might also like
Interleukin-7 unveils Pathogen-Specific T Cells by enhancing Antigen-Recall responses